Citius Oncology AI Stock Analysis
Want to see CTOR full AI Analyst Report?
Citius Oncology (CTOR) AI Stock Analysis
Citius Oncology
(NASDAQ:CTOR)
CTOR scores low primarily due to weak financial performance (no revenue, widening losses, and rising cash burn), reinforced by bearish technicals (price below key moving averages and negative MACD). Corporate events are mixed—Nasdaq compliance risk is a notable headwind, while commercial momentum and board actions provide some offset—but not enough to materially lift the overall risk profile.
Citius Oncology (CTOR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $51.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 114.31K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 2.89
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 285
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Citius Oncology Business Overview & Revenue Model
Company Description
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cu...
How the Company Makes Money
CTOR is a clinical-stage development company; publicly available information indicating recurring product revenue from approved and marketed therapies is null. As a result, the company’s operations are generally funded through external financing rath...
Citius Oncology Financial Statement Overview
Summary
Financial profile is weak: the company is pre-revenue (no revenue reported), losses have widened materially (EBIT around -$4.9M in 2022 to about -$23.5M in 2025 annual), and cash burn increased (operating cash flow to ~-$5.5M and free cash flow to ~-$11.2M in 2025 annual). The key positive is low leverage (debt-to-equity ~0.08–0.09), but shrinking equity and deeply negative ROE indicate ongoing funding risk.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
22Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.11M | 0 | 0 | 0 | 0 |
| Gross Profit | 3.77M | 0 | 0 | 0 | 0 |
| EBITDA | -43.13M | -23.49M | -20.57M | -12.12M | 0 |
| Net Income | -46.06M | -24.76M | -21.15M | -12.70M | -10.87M |
Balance Sheet | |||||
| Total Assets | 112.09M | 100.94M | 84.37M | 47.73M | 42.69M |
| Cash, Cash Equivalents and Short-Term Investments | 16.56M | 3.92M | 112 | 0 | 0 |
| Total Debt | 10.21M | 3.80M | 3.80M | 0 | 0 |
| Total Liabilities | 71.71M | 56.08M | 38.23M | 22.20M | 6.42M |
| Stockholders Equity | 40.38M | 44.87M | 46.14M | 25.54M | 36.27M |
Cash Flow | |||||
| Free Cash Flow | -19.71M | -5.49M | 126.35K | -601.30K | -47.97K |
| Operating Cash Flow | -19.71M | -5.49M | 126.35K | -601.30K | -47.97K |
| Investing Cash Flow | -12.93M | -5.75M | -5.00M | -1.32M | -67.32M |
| Financing Cash Flow | 49.48M | 15.17M | 4.87M | 1.66M | 67.66M |
Citius Oncology Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 0.61, below the 50-day MA of 0.80, and below the 200-day MA of 0.81, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 36.82 is Neutral, neither overbought nor oversold. The STOCH value of 30.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTOR.
Citius Oncology Risk Analysis
Citius Oncology disclosed 56 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCitius Oncology Peers Comparison
Overall Rating
GRFS70Outperform
BIIB69Neutral
OGN53Neutral
SRXH47Neutral- CTOR44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GRFS | 70Outperform | $7.55B | 15.94 | 8.83% | 3.19% | 6.15% | 35.26% |
| BIIB | 69Neutral | $37.44B | 107.37 | 1.86% | ― | 2.15% | -78.55% |
| OGN | 53Neutral | $3.65B | 17.58 | 22.11% | 0.58% | -3.21% | -58.19% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SRXH | 47Neutral | $19.03M | -0.01 | -97.77% | 5.68% | ― | ― |
| CTOR | 44Neutral | $52.32M | -1.16 | -102.97% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CTOR | Citius Oncology, Inc. | 0.55 | -0.78 | -58.35% | |
| BIIB | Biogen Inc. | 253.40 | 88.67 | 53.83% | |
| GRFS | Grifols SA | 8.84 | 0.23 | 2.73% | |
| SRXH | Srx Health Solutions Inc. | 0.88 | -13.38 | -93.83% | |
| SCLX | Scilex Holding Company | 1.62 | -9.51 | -85.44% | |
| OGN | Organon & Co. | 13.89 | 6.34 | 84.05% |
Citius Oncology Corporate Events
Citius Oncology Granted Nasdaq Extension to Regain Compliance
NegativeOn October 19, 2026, Citius Oncology reported that Nasdaq granted the company an extension until April 19, 2027, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company’s share...
Citius Oncology Shareholders Approve Directors and Auditor
PositiveOn September 29, 2026, Citius Oncology, Inc. held its 2026 annual meeting of stockholders, at which shareholders elected Class II directors Dr. Eugene Holuka, Robert Smith, and Carol Webb to three-year terms expiring at the 2029 annual meeting. The v...
Citius Oncology adds independent director to expanded board
PositiveOn August 10, 2026, Citius Oncology expanded its Board of Directors to nine members with the appointment of Jonathan Peri, Ph.D., J.D., as an independent director, following a unanimous Board vote earlier that month. The Board determined that Peri me...
Citius Oncology reports strong LYMPHIR commercial momentum
PositiveOn August 5, 2026, Citius Oncology reported strong commercial momentum for its CTCL therapy LYMPHIR, highlighting rapid growth in institutional uptake during the quarter ended June 30, 2026. New institutional accounts ordering LYMPHIR rose 78% quarte...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026